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Background: Pradofloxacin, a newly developed 8-cyano-fluoroquinolone, show enhanced activity against Gram-
positive organisms and anaerobes to treat canine and feline bacterial infections. The purpose of this cross-over
study was to measure the unbound drug concentration of pradofloxacin in the interstitial fluid (ISF) using
ultrafiltration and to compare the kinetics of pradofloxacin in serum, ISF and tissue using enrofloxacin as reference.
Results: After oral administration of enrofloxacin (5 mg/kg) and pradofloxacin (3 mg/kg and 6 mg/kg, respectively),
serum collection and ultrafiltration in regular intervals over a period of 24 h were performed, followed by tissue
sampling at the end of the third dosing protocol (pradofloxacin 6 mg/kg). Peak concentrations of pradofloxacin
(3 mg/kg) were 1.55±0.31 μg/ml in the ISF and 1.85±0.23 μg/ml in serum and for pradofloxacin (6 mg/kg)
2.71±0.81 μg/kg in the ISF and 2.77±0.64 μg/kg in serum; both without a statistical difference between ISF and
serum. Comparison between all sampling approaches showed no consistent pattern of statistical differences.
Conclusions: Despite some technical shortcomings the ultrafiltration approach appears to be the most sensitive
sampling technique to estimate pharmacokinetic values of pradofloxacin at the infection site. Pharmacokinetics –
Pradofloxacin – Ultrafiltration – Dog – Oral Administration.Background
Since first introduced in the 1960s, fluoroquinolones have
undergone continual modification [1]. The third gener-
ation of this substance group is not only characterised by
its broad-spectrum activity against gram-negative species
but also by an enhanced activity against gram-positive
bacteria and a high efficacy against anaerobes. In addition
its prolonged serum half-life permits a convenient once
daily dosage [1-4]. Pradofloxacin, an 8-cyano-fluoroquino-
lone and third generation drug, is has been developed
exclusively for the veterinary market. Compared to the
well-established enrofloxacin, which was the first fluoro-
quinolone exclusively developed for the veterinary market,
its structure differs in a bicyclic basic ammonium deriva-
tive in position C-7 as well as a cyano-group in position
C-8. The bicyclic amine is mainly responsible for the* Correspondence: Gregor.Hauschild@ukmuenster
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reproduction in any medium, provided the orincreased potency of the substance, while the cyano-group
is responsible for its enhanced activity against first- and
second-step fluoroquinolone resistant bacteria [1].
Since the majority of bacterial infections are extracel-
lular, optimisation of the antimicrobial drug concentra-
tion at the site of infection, i.e. in the interstitial fluid
(ISF), is important to reach a therapeutic effect [5].
Thus, investigation of the concentration of unbound
antimicrobial in the ISF is of great meaning and import-
ant to predict therapeutic efficacy. Ultrafiltration enables
minimally invasive measurement in vivo of these un-
bound substance concentrations in the ISF. In essence
consisting of a biocompatible hollow micro-fiber with a
semipermeable membrane and a sample vial under vac-
uum, this system enables continuous, selective uptake of
the substance from the examined tissue by using nega-
tive pressure and provides continuous tissue sampling in
awake, unrestrained animals. The system produces a
filtrate, whose molecular components do not exceed a
size of 30,000 d. Thus, larger proteins and cellular
components are filtered out, and direct analysis ofral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of the microdialysis technique such as small sample
volumes and low concentrations collected as well as the
system immanent continuous perfusion of the probe with
fluid which does not allow equilibrium between ISF and
perfusion fluid [6,7] are not supposed to appear using the
ultrafiltration technique. It was the aim of the present
study to investigate the pharmacokinetics of unbound
pradofloxacin using ultrafiltration and to compare the out-
come of this sampling technique to the results gained by
the analysis of standard serum and tissue samples.
Methods
Animal experiments were conducted under an ethic com-
mittee approved protocol in accordance with German
federal animal welfare legislation (Az 50.05-230-84/06),
which is in compliance with the guidelines outlined in the
NRC Guide for the Care and Use of Laboratory Animals.
All animals were housed in groups of two animals at the
Central Animal Laboratory of the Heinrich-Heine-Univer-
sity of Duesseldorf, Germany, University Hospital, and all
procedures were performed in that same facility.
Study design
The study followed a three-period three-treatment
cross-over design. Six healthy female beagle dogs (B.
Bomholt, 44579 Castrop-Rauxel, Germany) with a body
weight ranging from 11.5 to 16 kg were included. Treat-
ment started with administration of enrofloxacin 5 mg/kg,
followed by pradofloxacin 3 mg/kg and pradofloxacin
6 mg/kg. Each substance was given orally q24h for 6 days
followed by a washout period of at least seven days between
each treatment. Serum and ISF sampling started on the fifth
day of treatment at 0 (pretreatment) 0.5, 1, 2, 4, 8, 12 and
24 hours after administration.. When necessary, the dose
was adapted to the bodyweight of the test animals by
breaking the tablet into two or four equal parts. By the end
of the study, each dog had received each of three
treatments containing enrofloxacin 5 mg/kg, pradofloxacin
3 mg/kg and pradofloxacin 6 mg/kg.
Blood collection
Blood was collected from the Vena cephalica antebrachii
using a peripheral intravenous cannula (Braun, Melsungen,
Germany) and commercially available plastic tubes con-
taining a clot activator (Monovette, Sarstedt, Nümbrecht,
Germany). This was followed by centrifugation at
2.500 g for 10 min. Serum was separated and frozen at -
18°C until analysis.
Tissue sampling
Sacrification of the experimental animals was performed
within 1 - 1.5 h after the last dose of drug was
administered. This was followed by tissue sampling frombone, cartilage, skin, muscle, fat, liver, kidney and cere-
brospinal fluid (CSF). The bone and cartilage samples
were taken from the stifle joint (trochlea ossis femoris);
skin, muscle and fat were collected from the abdominal
wall (Musculus rectus abdominis, intra-abdominal fat).
Wedge biopsies were performed to collect liver and
kidney samples, whereas CSF was taken by puncture of
the subarachnoid space. All tissues were collected as
double samples, saved native in Falcon tubes (polypro-
pylene conical tubes 50 ml, Becton Dickinson labware,
USA) and frozen immediately at -18°C. CSF was saved
in Eppendorf tubes (Eppendorf microcentrifuge tubes,
2.0 ml, Eppendorf, Germany) and handled like the
tissue samples.
Ultrafiltration (collection of ISF)
Subcutaneous sampling of ISF was performed parallel to
blood collection using an in vivo ultrafiltration system
(BASi Inc., West Lafayette, IN, USA) in accordance to
the procedure published by Bidgood and Papich (2005)
[8]. This system consists of three main components: the
ultrafiltration (UF) probe, a hub assembly and a
vacutainer. The UF-3-12-probe had three loops of mem-
brane, and each membrane loop contained 12 cm of
semipermeable membrane which offered 36 cm of avail-
able membrane surface for ultrafiltration. The semiper-
meable membrane of this probe was characterised by a
molecular weight cut-off value of 30 kd, providing the
collection of samples of unbound drug fraction. In modi-
fication of the established procedure the non-permeable
part of the probe which extended to the exterior of the
animal was fixed with tape-flaps sutured to the skin and
was additionally secured by a feeding tube which
covered the probe to prevent bending. After connecting
the probe with the vacutainer, the system was protected
with a jacket made to fit for each dog.
HPLC analysis of serum, ISF and CSF
We investigated the test substance pradofloxacin
(VerafloxW, Bayer Animal Health GmbH, Germany) with
a molecular weight of 396.4 Da as well as the reference
substance enrofloxacin (BaytrilW, Bayer Vital GmbH,
Germany) with a molecular weight of 359.4 d with a limit
of quantification (LOQ) of 0.025 μg/ml using an identical
approach. For HPLC analysis a Turbulent Flow Chroma-
tography system 2300 HTLCTM (Cohesive Technologies
Inc.) with auto injector CTC HTS PAL (CTC Analytics
AG) coupled to a tandem mass spectrometer Sciex API
365 (Applied Biosystems) was used. As extraction column
we used a HTLCTM Cyclone 1 × 50 mm, 60 μm polymer
(Thermo Fisher). Serum and ISF samples were centrifuged
at 4°C and 15,000 g for 10 min, and an aliquot was trans-
ferred into an autosampler vial. After addition of the in-
ternal standard (pradofloxacin-d4 or enrofloxacin-ethyl
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into the HPLC. Sample pre-treatment was performed
directly in the HPLC system. The undiluted sample was
injected and transferred by the isocratic pump with a
high flow rate (5 ml/min of an acidic solution of ammo-
nium acetate containing 0.77 g ammonium acetate and
1.5 ml trifluoroacetic acid in 1 l water) to the extraction
column. After switching to the elution position the
analyte was eluted with the mobile phase (gradient from
90% acidic solution of ammonium acetate and 10%
acetonitrile to 100% acetonitrile in 5 seconds, flow rate
1.5 ml /min) and transferred to the mass spectrometric
detector (split approximately 1:10). The analyte was
determined in the multiple-reaction-monitoring mode.
The calculation of the concentration was performed by
comparison with matrix-matched standards containing
the internal standard [9].
HPLC analysis of tissue samples
Tissue samples of muscle, fat, liver and kidney (1 g) were
extracted by homogenisation with 10 ml of a mixture of
acetonitrile (500 ml/l) and 0.1 ml/l formic acid. After
centrifugation of the suspension for approximately 10
min, an aliquot of the liquid phase was passed through a
0.2 μm filter. One ml of the filtrate was transferred into
an auto-sampler vial, and internal standard solution
(containing pradofloxacin-d4) was added. Analysis was
performed by Turbulent Flow Chromatography / Tan-
dem Mass Spectrometry as described above, but in
addition, after switching to the elution position, theFigure 1 Serum and ISF concentrations after oral administration of enanalyte was eluted to an analytical column (Chromolith
Speed Rod, 50 × 4.6 mm RP 18e, Merck) and then trans-
ferred to the mass spectrometer [10].
Samples of skin (100 to 200 mg) and cartilage (10 – 60
mg) were digested by shaking with 0.5 ml Proteinase K
solution for 48 h at 55°C. The resulting suspension was
acidified with 1.5 ml diluted formic acid and treated in
an ultrasonic bath for 15 min. Bone samples were
treated with 20% formic acid for 72 h at 55°C on a shak-
ing machine. The resulting suspension was centrifuged
for 5 min at 6,000 g. The resulting suspensions were
added to styrene divinyl benzene (SCVB) polymer dis-
posable columns 500 mg/ 6 ml (Bond Elut ENV, Varian).
The elution was conducted with a mixture of acidic
acetonitrile and diluted formic acid [11]. After addition
of internal standard (pradofloxacin-d4), the HPLC ana-
lysis was performed as described above.
Pharmacokinetic and statistical analysis
A non-compartment analysis of serum and ISF data was
made. Pharmacokinetic parameters were calculated using
the software program WinNonlin 5.2 (Pharsight Corp.,
USA). Normal distribution of variables (model-residuals)
was confirmed by visual assessment of normal probability
plots. Comparisons of pharmacokinetic parameters at
ISF and serum between doses was calculated by t-test
for paired observations. Analyses were carried out with
the statistical software SAS, version 9.3 (SAS Institute,
Cary, NC).rofloxacin (5 mg/kg), expressed as mean ± SD. ISF ♦ Serum ■.
Figure 2 Serum and ISF concentrations after oral administration of pradofloxacin (3 mg/kg), expressed as mean ± SD. ISF ♦ Serum ■.
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No adverse effects after oral administration of enrofloxacin
(5 mg/kg) and pradofloxacin (3 mg/kg and 6 mg/kg, re-
spectively) were observed in any of the dogs. The ultrafil-
tration procedure was well tolerated in all dogs involved
in this study. A total of 288 samples of serum and ISFFigure 3 Serum and ISF concentrations after oral administration of prand 48 double samples of tissue were taken. From these
a total of 100% of tissue biopsies (n=48), 89% of serum
samples (n=129) and 52 % of ISF samples (n=75) could
be evaluated. Among these, for the third treatment
(pradofloxacin 6 mg/kg) 95 % of serum samples (n=46),
87 % of ISF samples (n=42) and 100% of tissue biopsiesadofloxacin (6 mg/kg), expressed as mean ± SD. ISF ♦ Serum ■.
Table 2 Pharmacokinetic parameters (mean ± SD) for
pradofloxacin after oral administration (3 mg/kg) in dogs
Parameter Units PO Serum PO ISF
Cmax μg/ml 1.85±0.23
* 1.55±0.31*
AUC24 h*μg/ml 16.18±4.28 21.19±8.12
AUCinf h*μg/ml 18.11±4.82# 29.95±11.41#
Tmax h 2.33±1.37
* 8±3.27*
T1/2 h 6.97±1.83
# 8.57±2.29#
T24 h 24±0 21±6
λz /h 0.11±0.03 0.08±0.02
MRTlast h 7.9±0.81 10.35±3.39
MRTinf h 11.27±3.11 14.78±4.12
Cmax maximum concentration; AUC24 area under the curve from time 0 to 24
hours; MRTlast mean residence time; λz first order rate constant of terminal
portion of the curve; T1/2 half-life; Tmax time to maximal concentration; T 24
time of final measurement; AUCinf area under the curve from 0 extrapolated to
infinity; MRTinf mean residence time from time 0 extrapolated to infinity for
non-infusion models; * statistical different (p ≤ 0,05); # no statistical difference
(p ≤ 0,05).
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comparative estimation of all three matrices. Serum and
ISF concentrations after oral administration of 5 mg/kg
enrofloxacin, 3 mg/kg pradofloxacin and 6 mg/kg pra-
dofloxacin were plotted on a semilogarithmic graph for
analysis (Figures 1, 2, 3); pharmacokinetic parameters
are expressed as the arithmetic mean ± standard devi-
ation in Tables 1, 2, 3.
Tissue concentrations after administration of pra-
dofloxacin (6 mg/kg) are given as the arithmetic mean ±
standard deviation in Table 4.
ISF values
ISF values of pradofloxacin following oral administration
of 3 mg/kg and 6 mg/kg were statistically different for
AUCInf (29.95 ± 11.41 μg* h/ml vs. 43.38 ± 17.54 μg*h/
ml, p = 0.0427) and Cmax (1.55 ± 0.31 μg/ml vs. 2.71 ±
0.8 μg/ml, p = 0.0142). This was not true for Tmax (8 ±
3.27 h vs. 6 ± 3.35 h, p = 0.1817) and T1/2 (8.57 ± 2.29 h
vs. 8.35 ± 3.5 h, p = 0.3747). Enrofloxacin oral ISF values
reached a mean peak concentration of 0.59 ± 0.43 μg/ml
at Tmax 5.33 ± 2.31 h with T1/2 at 4.47 ± 0.42 and an
AUCInf of 7.54 ± 3.89 μg*h/ml.
Serum values
Oral serum values of pradofloxacin 3 mg/kg and 6 mg /kg
were statistically different for AUCInf (18.11 ± 4.82 μg*
h/ml vs. 26.76 ± 6.27 μg*h/ml, p = 0.0040) and Cmax
(1.85 ± 0.23 μg/ml vs. 2.77 ± 0.63 μg/ml, p = 0.0183).
Tmax (2.33 ± 1.37 h vs. 2 ± 1.1 h, p = 0.4650) and T1/2
(6.97 ± 1.83 h vs. 6.31 ± 1.74 h (p = 0.4581) showed
no statistical difference.
Enrofloxacin oral serum values reached a mean peak
concentration of 1.89 ± 0.83 μg/ml at Tmax 1.66 ± 0.52Table 1 Pharmacokinetic parameters (mean ± SD) for
enrofloxacin after oral administration (5 mg/kg) in dogs
Parameter Units PO Serum PO ISF
Cmax μg/ml 1.89±0.83 0.59±0.43
AUC24 h*μg/ml 7.42±3.03 5.19±4.32
AUCinf h*μg/ml 7.59±3.09 7.54±3.89
Tmax h 1.66±0.52 5.33±2.31
T1/2 h 3.18±1.5 4.47±0.42
T24 h 20±6.92 16±6.92
λz /h 0.26±0.11 0.16±0.02
MRTlast h 3.70±0.55 7.30±1.14
MRTinf h 4.04±0.58 8.25±0.79
Cmax maximum concentration; AUC24 area under the curve from time 0 to 24
hours; MRTlast mean residence time; λz first order rate constant of terminal
portion of the curve; T1/2 half-life; Tmax time to maximal concentration; T 24
time of final measurement; AUCinf area under the curve from 0 extrapolated to
infinity; MRTinf mean residence time from time 0 extrapolated to infinity for
non-infusion models.h with T1/2 at 3.18 ± 1.5 h and an AUCInf of 7.59 ±
3.09 μg*h/ml.
Serum and ISF values in comparison
Serum and ISF values of pradofloxacin 3 mg/kg were
statistically different for Cmax (p = 0.0402) and Tmax (p =
0.0114) but not for AUCINf (p = 0.1682) and T1/2 (p =
0.5146). Serum and ISF values of pradofloxacin 6 mg/kg
were statistically different for Tmax (p = 0.0103) but not
for Cmax (p = 0.8071), AUCINf (p = 0.0831) and T1/2 (p =
0.2178).
PK/PD ratios
Cmax/MIC and AUC24/MIC ratios were calculated for
the label dose of pradofloxacin 3 mg/kg based onTable 3 Pharmacokinetic parameters (mean ± SD) for
pradofloxacin after oral administration (6 mg/kg) in dogs
Parameter Units PO Serum PO ISF
Cmax μg/ml 2.77±0.63# 2.71±0.8#
AUC24 h*μg/ml 24.21±5.09 35.19±8.39
AUCinf h*μg/ml 26.76±6.27# 43.38±17.54#
Tmax h 2±1.1
* 6±3.35*
T1/2 h 6.31±1.74
# 8.35±3.5#
T24 h 24±0 24±0
λz /h 0.12±0.03 0.09±0.03
MRTlast h 7.16±1.31 10.16±1.83
MRTinf h 9.58±3.04 14.6±6.41
Cmax maximum concentration; AUC24 area under the curve from time 0 to 24
hours; MRTlast mean residence time; λz first order rate constant of terminal
portion of the curve; T1/2 half-life; Tmax time to maximal concentration; T 24
time of final measurement; AUCinf area under the curve from 0 extrapolated to
infinity; MRTinf mean residence time from time 0 extrapolated to infinity for
non-infusion models; * statistical different (p ≤ 0,05); # no statistical difference
(p ≤ 0,05).
Table 4 Tissue concentrations (mean± SD) after oral
administration (6 mg/kg) of pradofloxacin in dogs
(measured at 1-1.5 hours after drug administration)
Tissue Units Concentration
Skin μg/mg 0.535±0.290
Fat μg/mg 0.0756±0.0624
Muscle μg/mg 0.709±0.455
Cartilage μg/mg 2.614±1.450
Bone μg/mg 0.361±0.0987
Liver μg/mg 1.501±1.322
Kidney μg/mg 1.435±1.083
CSF μg/ml 0.107±0.063
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bacteria specified in the Veraflox SPC, i.e. Staphylococcus
(pseud)intermedius, Escherichia coli and Pasteurella
multocida (Table 5).
The UF-device
There were some shortcomings affecting the sample col-
lection, which were associated with the UF-device. These
included dislocation of the UF-probe followed by the
need for re-implantation in four of 18 sampling periods
(22%) at the start of the study. Insufficient vacuum
resulting in either lack of flow or lack of volume causing
drug concentrations below the limit of quantification
was assumed for 12 of 18 sampling periods (66%). We
assumed that the hub assembly was the critical system
component causing these shortcomings. After applica-
tion of 6 mg/kg pradofloxacin this phenomenon oc-
curred only in two test animals; thus, 42 of 48 (87%) of
the samples for this dosing protocol could be utilized.
Discussion
Bacterial infections mainly occur in the extracellular
space. Keeping in mind that from a clinical point of view
tissue- and in detail ISF-concentrations are often
considered better evidence of drug effectiveness than
serum concentrations [13,14] it is the therapeutic aim to
apply a dosing scheme that will result in a drug concen-
tration in the ISF above the minimal inhibitory concen-
tration (MIC) [15]. For the newly developed 8-cyano
-fluoroquinolone pradofloxacin only few studies toTable 5 Pharmakokinetik/Pharmakodynamic ratios of oral pra
and ISF
Pasteurella multocida
(MIC90 = 0.015 μg/ml)
Esc
(MIC90
Serum ISF Serum
Cmax/MIC90 123.3 103.3 61.7
AUC0-24/MIC90 1078.7 1412.7 539.3determine drug concentrations in the ISF are available
[16,17]. In-vivo UF which was first published in a study
by Janle-Swain et al. in 1987 [18] in this regard seems to
be a promising alternative to standard methods. In
contrast to microdialysis, ultrafiltration establishes an
equilibrium across the capillary for the unbound drug
concentration as stated theoretically by Ögren & Cars
(1985) [19] and being confirmed by Bidgood & Papich
(2005) [8] which is essential to directly estimate the rele-
vant concentrations at the site of infection. To the
knowledge of the authors, the present study is the first
to compare pharmacokinetic data of pradofloxacin based
on UF with serum and tissue data from dogs.
Comparison of the serum and ISF concentrations of the
reference fluoroquinolone enrofloxacin with the results of
Frazier et al. (2000) [20] and those of Bidgood & Papich
(2005) [8] showed similar results. This confirmed the val-
idity of the chosen study design and methods. While the
kinetics of enrofloxacin displayed a continuous increase of
the concentration in the ISF during the absorption phase
after application, for pradofloxacin a decrease in concen-
tration was observed initially between the first two meas-
uring time points (more pronounced with the dose 6 mg/
kg than with 3 mg/kg) followed by a continuous increase
to a maximum drug concentration (Figures 1, 2, 3). It can
be hypothesized that this observation is a result of the
study design using a multiple dosing regime with lack of a
“baseline”. On the other hand a comparatively slightly
slower absorption of pradofloxacin may be ruled out, since
this effect could not be demonstrated in the analysis of
the serum samples. The delay seems to originate from the
drug exiting the vascular system into the ISF. However,
this only applies to the initial absorption phase; later the
increase of the drug concentration became similar for
enrofloxacin and pradofloxacin in both doses. What is
more due to the shortcomings of the UF-system described
later on we abandoned to calculate a lag time for the ISF
samples which may also have influenced this phenomenon.
The initial concentrations following application of 3 and 6
mg/kg pradofloxacin were always above the MIC90 values
for most relevant target bacteria which - in context with
the proven post-antibiotic effect of pradofloxacin [14,21]
confirmed the efficacy of the chosen dosing interval. The
maximal drug concentration of pradofloxacin in the ISF
(Cmax μg/ml: 1.55 ± 0.31 for the dose 3 mg/kg exceededdofloxacin values (3 mg/kg oral administration) in serum
herichia coli
= 0.03 μg/ml)
Staphylococcus pseudintermedius
(MIC90 = 0.12 μg/ml)
ISF Serum ISF
51.7 15.4 12.9
706.3 134.8 176.6
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the SPC bacterial pathogens Pasteurella multocida,
Escherichia coli and Staphylococcus pseudintermedius
[12]. PK/PD integrated models link drug concentrations
to their activity on bacterial pathogens [22]. To minimize
or prohibit the selection of resistant organisms at present
for fluoroquinolones a ratio of the maximum serum
concentration to MIC (Cmax/MIC) >10 and a ratio of the
area under concentration-time curve over 24 h to MIC
(AUC24/MIC) >125 [23,24] are widely used. Based on the
present study the pradofloxacin standard dosage protocol
of 3 mg/kg [25] would exhibit a good efficacy against the
label organisms with MIC90 of ≤ 0.12 μg/ml. The dosage
interval of 24 h thereby was confirmed by the terminal
half-life in the serum and ISF for both doses (6.97/6.3 h
and 8.5/8.35 h, respectively).
With regard to the protein binding of pradofloxacin of
29 – 37% [26] the suggested adjustment for protein bind-
ing in pharmacokinetic-pharmacodynamic assessments
[27] seems to be unnecessary in this case due to the fact
that calculated unbound drug concentration in serum is
lower than the active drug concentration in the ISF. This
is similar to results presented by Messenger et al. (2012)
[28] for enrofloxacin and may be a phenomenon specific
for fluoroquinolones. Although pharmacokinetic analysis
of tissue samples is accepted as a standard method to
analyse drug distribution in tissue [29], it has several
limitations. Since infections addressed by fluoroquinolones
are localized in the extracellular space i.e. the ISF, the drug
concentrations at site of infection are under- or over-
estimated when determining them in tissue homogenates
[6,30]. The concentrations in tissue samples result from a
mixture of different compartments and are thus difficult
to interpret [31]. Furthermore, the possibility for continu-
ous and extensive sampling is very limited in the light of
ethical considerations. True determination of the maximal
tissue concentration is questionable on this basis. The
lower tissue concentrations compared to other studies
[16] is to be seen in context with the short time span
between final drug application and euthanasia of the ex-
perimental animals. At the time of euthanasia the concen-
tration development, as shown by the serum and ISF
analysis, was generally still in the absorption phase. Over
all serum values are a much better predictor of ISF
concentrations than total tissular concentrations but ISF-
samples proved to illustrate best the relevant concentra-
tion values at the site of infection. The advantages of the
in-vivo technique of UF have been described in several
pharmacokinetic studies. These advantages include data
collection directly at the action site of the tested drug in
different tissues over a long time period, direct sample
analysis without extraction steps, maintenance of an equi-
librium during sampling and last but not least reduced
strain on the tested animal [19,32,33].However, the authors recognize some immanent sys-
tem disadvantages.
The low number of usable samples from the UF
(52.08%) could only be assigned to a dislocation or
tearing of the membrane-carrying probe in two cases.
Most failures were a result of an insufficient vacuum
resulting in inadequate ISF flow into the receptive vial.
We identified the hub assembly, which consists of three
individual components, as the source of the problem.
Leakage occurred repeatedly and could not be resolved
completely. Because of the unstable negative pressure in
the used UF systems during the study duration, we did
not arithmetically adjust the resulting time delay during
sampling, which would generally be useful for optimal
comparability of the serum samples regarding evalu-
ation of the pharmacokinetic parameters [34]. Despite
the high number of losses, 87% of the ISF samples could
be evaluated for the higher dose rate (pradofloxacin
6 mg/kg).
Conclusions
In conclusion, peak concentrations detected at the site
of infection after oral administration of pradofloxacin
using a standard dosage protocol of 3 mg/kg exceed the
MIC90 values for indicated and most other bacterial
targets. Based on ISF-related PK/PD ratios good clinical
efficacy against the bacteria listed in the Veraflox SPC
would be predicted. Considering the comparison between
serum, ISF and tissue data the authors regard ultrafiltration
as the most effective method for pharmacokinetic analysis
of fluoroquinolones, since it most realistically reflects the
situation at the target site. Furthermore, it is the method
with the least invasiveness and stress for the test animal.
After elimination of the technical disadvantages of the sys-
tem, ultrafiltration could become a useful addition to
current methods in pharmacokinetics analysis, and perhaps
even replace them.
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